Keytruda

While Moderna grabbed headlines with a 177% jump, its partner Merck recorded its best day since 2009. Morgan Stanley has upgraded its recommendation, highlighting the company's potential beyond its flagship drug, despite the looming patent expiration.

An experimental personalized cancer vaccine for melanoma from Merck and Moderna has shown positive preliminary results in its first late-stage trial. The combination therapy significantly extended the time patients lived without recurrence.

An experimental personalized cancer vaccine from Merck and Moderna has shown positive preliminary results in a Phase 3 trial. The combination therapy significantly reduced the risk of melanoma recurrence.